Oxford BioMedica PLC
LSE:OXB

Watchlist Manager
Oxford BioMedica PLC Logo
Oxford BioMedica PLC
LSE:OXB
Watchlist
Price: 619 GBX Market Closed
Market Cap: 745.9m GBX

Wall Street
Price Targets

OXB Price Targets Summary
Oxford BioMedica PLC

Wall Street analysts forecast OXB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for OXB is 748.85 GBX with a low forecast of 455.51 GBX and a high forecast of 1 018.5 GBX.

Lowest
Price Target
455.51 GBX
26% Downside
Average
Price Target
748.85 GBX
21% Upside
Highest
Price Target
1 018.5 GBX
65% Upside
Oxford BioMedica PLC Competitors:
Price Targets
688366
Shanghai Haohai Biological Technology Co Ltd
49% Upside
DVAX
Dynavax Technologies Corp
92% Upside
EXEL
Exelixis Inc
6% Upside
GILD
Gilead Sciences Inc
11% Upside
PBYI
Puma Biotechnology Inc
11% Downside
KURN
Kuros Biosciences AG
15% Upside
GNFT
Genfit SA
90% Upside
SPRB
Spruce Biosciences Inc
167% Upside

Revenue
Forecast

Revenue Estimate
Oxford BioMedica PLC

For the last 13 years the compound annual growth rate for Oxford BioMedica PLC's revenue is 24%. The projected CAGR for the next 3 years is 31%.

24%
Past Growth
31%
Estimated Growth
Estimates Accuracy
1%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Oxford BioMedica PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Net Income
Forecast

Net Income Estimate
Oxford BioMedica PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-38%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is OXB's stock price target?
Price Target
748.85 GBX

According to Wall Street analysts, the average 1-year price target for OXB is 748.85 GBX with a low forecast of 455.51 GBX and a high forecast of 1 018.5 GBX.

What is Oxford BioMedica PLC's Revenue forecast?
Projected CAGR
31%

For the last 13 years the compound annual growth rate for Oxford BioMedica PLC's revenue is 24%. The projected CAGR for the next 3 years is 31%.

Back to Top